{"id":"https://openalex.org/W1829720201","doi":null,"title":"Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.","display_name":"Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.","publication_year":2004,"publication_date":"2004-10-01","ids":{"openalex":"https://openalex.org/W1829720201","mag":"1829720201","pmid":"https://pubmed.ncbi.nlm.nih.gov/15468359"},"language":"en","primary_location":{"id":"pmid:15468359","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15468359","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of rheumatology","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103728339","display_name":"Niveditha Mohan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Niveditha Mohan","raw_affiliation_strings":["Avera Research Institute, Sioux Falls, South Dakota 57105, USA. nmohan@pol.net"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avera Research Institute, Sioux Falls, South Dakota 57105, USA. nmohan@pol.net","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033365693","display_name":"Evelyne T. Edwards","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Evelyne T Edwards","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067418286","display_name":"Thomas R. Cupps","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas R Cupps","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075097703","display_name":"Nancy R. Slifman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nancy Slifman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008940187","display_name":"Lee Jong-Hoon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jong-Hoon Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109858069","display_name":"Jeffrey N. Siegel","orcid":"https://orcid.org/0000-0002-2387-1365","observed_orcids":["https://orcid.org/0000-0002-2387-1365"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey N Siegel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5113569674","display_name":"M. Miles Braun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Miles Braun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":7.7304,"has_fulltext":false,"cited_by_count":200,"citation_normalized_percentile":{"value":0.98138614,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"31","issue":"10","first_page":"1955","last_page":"8"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.37299999594688416,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.37299999594688416,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.22390000522136688,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.18160000443458557,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/leukocytoclastic-vasculitis","display_name":"leukocytoclastic vasculitis","score":1.0},{"id":"https://openalex.org/keywords/tumor-necrosis-factor-inhibitors","display_name":"tumor necrosis factor inhibitors","score":0.921999990940094},{"id":"https://openalex.org/keywords/etanercept","display_name":"etanercept","score":0.9850000143051147},{"id":"https://openalex.org/keywords/infliximab","display_name":"infliximab","score":1.0},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.7900000214576721},{"id":"https://openalex.org/keywords/drug-induced-vasculitis","display_name":"drug-induced vasculitis","score":0.8199999928474426},{"id":"https://openalex.org/keywords/cutaneous-vasculitis","display_name":"cutaneous vasculitis","score":0.765999972820282},{"id":"https://openalex.org/keywords/rechallenge","display_name":"drug rechallenge","score":0.7129999995231628},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.5640000104904175},{"id":"https://openalex.org/keywords/adverse-event-reporting","display_name":"adverse event reporting","score":0.44600000977516174}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9693979024887085},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.8708961009979248},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.826202392578125},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.8165208101272583},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.5263558626174927},{"id":"https://openalex.org/C2776015282","wikidata":"https://www.wikidata.org/wiki/Q644318","display_name":"Vasculitis","level":3,"score":0.49190759658813477},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.4708307087421417},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4578401744365692},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.453241765499115},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4370187819004059},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.390403687953949},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.34516090154647827},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068800","descriptor_name":"Etanercept","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069285","descriptor_name":"Infliximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012216","descriptor_name":"Rheumatic Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018124","descriptor_name":"Receptors, Tumor Necrosis Factor","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018366","descriptor_name":"Vasculitis, Leukocytoclastic, Cutaneous","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D018366","descriptor_name":"Vasculitis, Leukocytoclastic, Cutaneous","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018366","descriptor_name":"Vasculitis, Leukocytoclastic, Cutaneous","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:15468359","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15468359","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of rheumatology","raw_type":"Journal Article"},{"id":"mag:1829720201","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15468359","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W29335601","https://openalex.org/W1524649973","https://openalex.org/W1889000785","https://openalex.org/W1974903457","https://openalex.org/W2007830806","https://openalex.org/W2026905014","https://openalex.org/W2073835837","https://openalex.org/W2076164551","https://openalex.org/W2080482139","https://openalex.org/W2083328249","https://openalex.org/W2118189989","https://openalex.org/W2134162780","https://openalex.org/W2142273705","https://openalex.org/W2165496443","https://openalex.org/W2314052274","https://openalex.org/W2317111303","https://openalex.org/W2321453230","https://openalex.org/W2326330820","https://openalex.org/W2328587823","https://openalex.org/W2406194751","https://openalex.org/W2413173458"],"related_works":["https://openalex.org/W29335601","https://openalex.org/W4367298890","https://openalex.org/W2158964732","https://openalex.org/W1771761420","https://openalex.org/W2052416186","https://openalex.org/W2939392870","https://openalex.org/W2416817226","https://openalex.org/W4417171246","https://openalex.org/W2809064117","https://openalex.org/W2134267423"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"describe":[2],"the":[3,12,28,80,87,113,128,153,209],"clinical":[4],"features":[5],"of":[6,14,27,39,53,55,65,79,99,108,127,131,152,168,192,211,218,226],"leukocytoclastic":[7],"vasculitis":[8],"(LCV)":[9],"associated":[10,196,207],"with":[11,157,173,197,201,208,236],"use":[13,191],"tumor":[15],"necrosis":[16],"factor-alpha":[17],"(TNF-alpha)":[18],"blockers.":[19],"METHODS:":[20],"The":[21],"Adverse":[22],"Events":[23],"Reporting":[24],"System":[25],"(AERS)":[26],"US":[29],"Food":[30],"and":[31,73,86,155,159,177,231],"Drug":[32],"Administration":[33],"(FDA)":[34],"was":[35,144],"queried":[36],"for":[37,96,233],"reports":[38],"patients":[40,102,117,133,162,179,188],"who":[41,118,141],"developed":[42],"LCV":[43,66,169,184,227],"during":[44],"or":[45,49,105],"after":[46],"starting":[47],"etanercept":[48,71,121],"infliximab":[50,76,143],"from":[51],"date":[52],"approval":[54],"each":[56],"agent":[57],"through":[58],"September":[59],"6,":[60],"2002.":[61],"RESULTS:":[62],"Thirty-five":[63],"cases":[64,85],"were":[67,83,93],"identified,":[68],"20":[69],"following":[70,75],"administration":[72],"15":[74],"administration.":[77],"Seventeen":[78],"35":[81,100],"(48.5%)":[82],"biopsy-proven":[84],"others":[88],"had":[89,103,119,122],"skin":[90,109],"lesions":[91,110,124,149,185,214],"that":[92],"clinically":[94],"typical":[95],"LCV.":[97,198,212],"Twenty-two":[98],"(62.8%)":[101],"complete":[104],"marked":[106],"improvement":[107],"upon":[111],"stopping":[112],"TNF-alpha":[114,175,202],"blocker.":[115],"Three":[116],"received":[120,142],"continuing":[123,148,190],"despite":[125,150,189],"discontinuation":[126,151,217],"drug;":[129],"one":[130],"these":[132],"improved":[134,186,215],"when":[135],"switched":[136],"to":[137,146],"infliximab.":[138],"One":[139],"patient":[140],"reported":[145],"have":[147],"drug":[154],"treatment":[156],"prednisone":[158],"antihistamines.":[160],"Six":[161],"experienced":[163],"a":[164,174,180],"positive":[165],"rechallenge":[166,182],"(recurrence":[167],"on":[170,216],"restarting":[171],"therapy":[172,220],"blocker)":[176],"3":[178],"negative":[181],"phenomenon.":[183],"in":[187,221],"concomitant":[193],"medications":[194],"reportedly":[195],"CONCLUSION:":[199],"Therapy":[200],"blocking":[203],"agents":[204],"may":[205],"be":[206,229],"development":[210],"Skin":[213],"anti-TNF-alpha":[219],"most":[222],"patients.":[223],"Other":[224],"causes":[225],"should":[228],"excluded,":[230],"evaluation":[232],"systemic":[234],"involvement":[235],"appropriate":[237],"investigations":[238],"is":[239],"recommended.":[240]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":13},{"year":2014,"cited_by_count":13},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":11}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}